• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA conditionally approves first oral canine lymphoma treatment

January 12, 2021
dvm360 Staff
dvm360, dvm360 February 2021, Volume 52,

Laverdia-CA1 provides an additional treatment option for dogs suffering from this devastating illness.

The US Food and Drug Administration announced today the conditional approval of Laverdia-CA1 (verdinexor tablets) to treat canine lymphoma.

The first conditionally approved oral treatment for dogs with lymphoma, Laverdia-CA1 prevents certain proteins from leaving the nucleus of cancer cells, thus allowing the proteins to control the growth and prevent the spread of cancerous cells. It is the second conditionally FDA-approved treatment for canine lymphoma. (Tanovea-CA1, an injectable, received conditional FDA approval in 2016.) Laverdia-CA1 is administered orally twice a week at home, with at least 72 hours between doses.

“Lymphoma is a devastating cancer in dogs, with few FDA-approved treatments available. This conditional approval provides a much-needed option to treat dogs with lymphoma,” says Steven M. Solomon, DVM, MPH, director of the FDA’s Center for Veterinary Medicine, in this FDA release. “We are encouraged to see drug companies bring forward applications for products to treat serious diseases, even if they affect relatively small populations.”

Conditional approval, which is an option for drugs intended for minor use in major species, provides veterinarians with access to necessary treatments while the pharmaceutical company gathers additional efficacy data. According to the FDA website, a company has up to 5 years to complete effectiveness studies to support full approval.

Advertisement

Laverdia-CA1’s reasonable expectation of efficacy was demonstrated in a study of 58 client-owned dogs of various breeds, weights, and genders with B- or T-cell lymphoma. All participants were followed for at least 8 months. The dogs were either newly diagnosed with lymphoma or in their first relapse after completing a single- or multi-agent chemotherapy regimen. Most of the dogs had stage III disease (generalized lymph node enlargement).

After verdinexor administration, 17 of the 58 dogs (29%) showed no progression of lymphoma for at least 56 days. Of these dogs, 3 showed no progression for at least 182 days.

The most common adverse reactions associated with verdinexor administration include anorexia, vomiting, diarrhea, weight loss, lethargy, increased water intake, increased urination, elevated liver enzymes, and low platelet count. Laverdia-CA1 should be administered immediately after eating, thus increasing the amount of drug absorbed into the bloodstream. Pregnant women, women who may become pregnant, nursing women, and children should not handle or administer Laverdia-CA1 or touch the feces, urine, vomit, or saliva of treated dogs.

Laverdia-CA1 is available by prescription only. To learn more about this new drug, go here.

download issueDownload Issue: dvm360 February 2021

Related Content:

Breaking NewsProductsClinicalMedicalOncologydvm360 February 2021
Morris Animal Foundation funds study on environmental toxins and lymphoma
Morris Animal Foundation funds study on environmental toxins and lymphoma
Study evaluating potential treatment for degenerative myelopathy receives funding
Study evaluating potential treatment for degenerative myelopathy receives funding
Details of new pet performance supplement line revealed
Details of new pet performance supplement line revealed

Advertisement

Latest News

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

CityVet Celina opens in Prosper, Texas

View More Latest News
Advertisement